(Albany, USA) DelveInsight’s “Primary Hyperoxaluria Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Primary Hyperoxaluria, historical and forecasted epidemiology as well as the Primary Hyperoxaluria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Primary Hyperoxaluria market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Primary Hyperoxaluria market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Primary Hyperoxaluria treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Primary Hyperoxaluria market.
Request for a Free Sample Report @ Primary Hyperoxaluria Market Insight
Some facts of Primary Hyperoxaluria market report are:
- According to DelveInsight’s analysis, the market size for primary hyperoxaluria reached USD 81 million in 2021 across the 7MM and is expected to grow with a significant CAGR by 2032.
- DelveInsight’s analysis reveals that the overall prevalent population of primary hyperoxaluria in the 7MM was reported as ~12K in 2021.
- Prominent companies working in the domain of primary hyperoxaluria, including Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, OxThera, Allena Pharmaceuticals, Biocodex, and others, are actively working on innovative drugs for primary hyperoxaluria. These novel primary hyperoxaluria therapies are anticipated to enter the primary hyperoxaluria market in the forecast period and are expected to change the market.
- Some of the key therapies for primary hyperoxaluria treatment include Lumasiran, DCR-PHXC, Oxabact (OC5-DB-02), Reloxaliase (ALLN-177), Stiripentol (Diacomit), and others.
Primary Hyperoxaluria Overview
Primary Hyperoxaluria (PH) is a rare genetic disorder characterized by the overproduction of oxalate, a substance that combines with calcium to form kidney and urinary tract stones. This condition arises due to mutations in genes responsible for enzymes that help process glyoxylate, leading to its conversion into oxalate instead. The three known types— Primary Hyperoxaluria 1, Primary Hyperoxaluria 2, and Primary Hyperoxaluria 3—are caused by mutations in the AGXT, GRHPR, and HOGA1 genes, respectively.
Primary Hyperoxaluria often manifests in childhood with recurrent kidney stones, urinary tract infections, and potential kidney damage. As the disease progresses, excessive oxalate can accumulate in bones, eyes, heart, and skin, leading to a condition called oxalosis. Severe cases may result in end-stage renal disease (ESRD), necessitating dialysis or kidney transplantation.
Primary Hyperoxaluria Diagnosis typically involves genetic testing, urine analysis for oxalate levels, and liver enzyme assays. Early detection is crucial for managing the condition and preventing complications. Primary Hyperoxaluria Treatment strategies focus on reducing oxalate levels through high fluid intake, low-oxalate diet, and medications like potassium citrate. In advanced cases, combined liver and kidney transplantation may be necessary.
Ongoing research aims to develop gene therapies and other novel treatments to better manage and potentially cure Primary Hyperoxaluria, improving the quality of life for affected individuals.
Learn more about Primary Hyperoxaluria treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Primary Hyperoxaluria Treatment Market
Primary Hyperoxaluria Market
The Primary Hyperoxaluria market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Primary Hyperoxaluria market trends by analyzing the impact of current Primary Hyperoxaluria therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Primary Hyperoxaluria market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Primary Hyperoxaluria market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Primary Hyperoxaluria market in 7MM is expected to witness a major change in the study period 2019-2032.
Primary Hyperoxaluria Epidemiology
The Primary Hyperoxaluria epidemiology section provides insights into the historical and current Primary Hyperoxaluria patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Primary Hyperoxaluria market report also provides the diagnosed patient pool, trends, and assumptions.
Primary Hyperoxaluria Epidemiology Segmentation:
- Primary Hyperoxaluria Prevalent Cases
- Diagnosed Primary Hyperoxaluria Prevalent Cases
- Gender-specific Primary Hyperoxaluria Diagnosed Prevalent Cases
- Age-specific Diagnosed Primary Hyperoxaluria Prevalent Cases
- Type-specific Diagnosed Primary Hyperoxaluria Prevalent Cases
Explore more about Primary Hyperoxaluria Epidemiology @ Primary Hyperoxaluria Prevalence
Primary Hyperoxaluria Drugs Uptake
This section focuses on the uptake rate of the potential Primary Hyperoxaluria drugs recently launched in the Primary Hyperoxaluria market or expected to be launched in 2019-2032. The analysis covers the Primary Hyperoxaluria market uptake by drugs, patient uptake by therapies, and sales of each drug.
Primary Hyperoxaluria Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Primary Hyperoxaluria market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Primary Hyperoxaluria Pipeline Development Activities
The Primary Hyperoxaluria report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Primary Hyperoxaluria key players involved in developing targeted therapeutics.
Request for a sample report to understand more about the Primary Hyperoxaluria pipeline development activities @ Primary Hyperoxaluria Therapies and Drugs
Primary Hyperoxaluria Therapeutics Assessment
Major key companies are working proactively in the Primary Hyperoxaluria Therapeutics market to develop novel therapies which will drive the Primary Hyperoxaluria treatment markets in the upcoming years are Oxthera, Allena Pharmaceuticals, Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, Biocodex, and others.
Learn more about the emerging Primary Hyperoxaluria therapies & key companies @ Primary Hyperoxaluria Clinical Trials and FDA Approvals
Primary Hyperoxaluria Report Key Insights
1. Primary Hyperoxaluria Patient Population
2. Primary Hyperoxaluria Market Size and Trends
3. Key Cross Competition in the Primary Hyperoxaluria Market
4. Primary Hyperoxaluria Market Dynamics (Key Drivers and Barriers)
5. Primary Hyperoxaluria Market Opportunities
6. Primary Hyperoxaluria Therapeutic Approaches
7. Primary Hyperoxaluria Pipeline Analysis
8. Primary Hyperoxaluria Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Primary Hyperoxaluria Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Primary Hyperoxaluria Competitive Intelligence Analysis
4. Primary Hyperoxaluria Market Overview at a Glance
5. Primary Hyperoxaluria Disease Background and Overview
6. Primary Hyperoxaluria Patient Journey
7. Primary Hyperoxaluria Epidemiology and Patient Population
8. Primary Hyperoxaluria Treatment Algorithm, Current Treatment, and Medical Practices
9. Primary Hyperoxaluria Unmet Needs
10. Key Endpoints of Primary Hyperoxaluria Treatment
11. Primary Hyperoxaluria Marketed Products
12. Primary Hyperoxaluria Emerging Therapies
13. Primary Hyperoxaluria Seven Major Market Analysis
14. Attribute Analysis
15. Primary Hyperoxaluria Market Outlook (7 major markets)
16. Primary Hyperoxaluria Access and Reimbursement Overview
17. KOL Views on the Primary Hyperoxaluria Market
18. Primary Hyperoxaluria Market Drivers
19. Primary Hyperoxaluria Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage